193 related articles for article (PubMed ID: 12743148)
1. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
3. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
Kara IO; Gonlusen G; Sahin B; Ergin M; Erdogan S
Saudi Med J; 2005 Aug; 26(8):1190-6. PubMed ID: 16127511
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
Chao J; Budd GT; Chu P; Frankel P; Garcia D; Junqueira M; Loera S; Somlo G; Sato J; Chow WA
Anticancer Res; 2010 Feb; 30(2):547-52. PubMed ID: 20332468
[TBL] [Abstract][Full Text] [Related]
5. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
[TBL] [Abstract][Full Text] [Related]
6. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
7. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications.
Navarro S; Giraudo P; Karseladze AI; Smirnov A; Petrovichev N; Savelov N; Alvarado-Cabrero I; Llombart-Bosch A
Anticancer Res; 2007; 27(4B):2457-63. PubMed ID: 17695539
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols.
Ahmed A; Gilbert-Barness E; Lacson A
Pediatr Dev Pathol; 2004; 7(4):342-7. PubMed ID: 15383930
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of P53 status in Ewing sarcoma.
de Alava E; Antonescu CR; Panizo A; Leung D; Meyers PA; Huvos AG; Pardo-Mindán FJ; Healey JH; Ladanyi M
Cancer; 2000 Aug; 89(4):783-92. PubMed ID: 10951341
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
[TBL] [Abstract][Full Text] [Related]
14. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.
Gabor F; Wollmann K; Theyer G; Haberl I; Hamilton G
Anticancer Res; 1994; 14(5A):1943-50. PubMed ID: 7847832
[TBL] [Abstract][Full Text] [Related]
15. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
16. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
[TBL] [Abstract][Full Text] [Related]
17. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
18. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
Yerushalmi R; Nordenberg J; Beery E; Uziel O; Lahav M; Luria D; Fenig E
Exp Oncol; 2007 Jun; 29(2):126-31. PubMed ID: 17704745
[TBL] [Abstract][Full Text] [Related]
19. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
20. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]